好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Longitudinal Evolution of White Matter Damage in Parkinson’s Disease
Movement Disorders
P3 - Poster Session 3 (12:00 PM-1:00 PM)
3-009
To investigate the longitudinal evolution of cerebral white matter (WM) micro- and macrostructural damage and its relationship with motor and non-motor symptoms in PD. 
Although WM involvement has been suggested to have a role in disease progression, previous studies showed controversial results regarding the longitudinal evolution of WM damage and its relationship with the clinical picture.

154 patients with PD underwent clinical assessment, cognitive evaluation and Magnetic Resonance Imaging (MRI) scan on a 1.5 Tesla scanner (including T2-weighted and diffusion tensor [DT]-MRI sequences) once a year over a follow-up time of 36 months. White matter lesions (WML) were manually identified on T2-weighted scans and the total WML volume was calculated for each subject. Applying tract-based spatial statistics, mean fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (axD) and radial diffusivity (radD) values of the total WM skeleton were extracted. Longitudinal regression models and Pearson correlation analyses between MRI and clinical/cognitive data were performed, adjusting for baseline motor impairment measured using the Unified Parkinson’s Disease Rating Scale part III (UPDRS-III).
Variables showing significant progression over follow-up included UPDRS-III score (p<0.001), WML volume (p<0.001), MD (p=0.005) and axD (p<0.001) global values. Longitudinal trajectories of MD, axD, and radD values significantly correlated with UPDRS-III (r ranging 0.24/0.37, p ranging 0.01/0.04) and Addenbrooke Cognitive Examination total score (r ranging -0.27/-0.29, p ranging 0.01/0.02). WML volume did not correlate with longitudinal alterations of motor and cognitive clinical variables.

Our study showed that longitudinal evolution of WM microstructural damage is associated with both motor and global cognitive deterioration in PD, whereas the WM macroscopic damage evolution is not associated with the disease progression. Moreover, our results suggest that longitudinal evolution of WM microstructural damage measured by DT-MRI might provide a sensitive biomarker of PD progression.
Authors/Disclosures
Edoardo G. Spinelli, MD
PRESENTER 		Dr. Spinelli has nothing to disclose.
Federica Agosta (San Raffaele Scientific Institute) Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC.
No disclosure on file
No disclosure on file
Elisabetta Pagani Elisabetta Pagani has nothing to disclose.
Iva Stankovic (Neurology Clinic, Clinical Center of Serbia, University of Belgrade) Iva Stankovic has nothing to disclose.
No disclosure on file
No disclosure on file
Elka Stefanova No disclosure on file
Vladimir S. Kostic, MD, PhD (Institute of Neurology CCS) Dr. Kostic has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche. An immediate family member of Dr. Kostic has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Alkaloid. The institution of Dr. Kostic has received research support from Ministry of 好色先生, Science and Technological Development of Serbia.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.